Group 1 - The stock of Baixin An-B (02185) experienced a significant increase, rising over 15% during trading, reaching a high of 10.77 HKD, marking a new high in over two years, with a closing increase of over 50% the previous day [1] - As of the report, the stock price is up 7.63%, currently at 10.01 HKD, with a trading volume of 61.17 million HKD [1] Group 2 - The American Heart Association (AHA) and the American College of Cardiology (ACC) have released an updated guideline for the prevention, detection, assessment, and management of adult hypertension, which includes significant revisions from the 2017 version [1] - The new guidelines aim to provide more precise clinical practice guidance to reduce cardiovascular disease (CVD) risk, with renal denervation (RDN) being introduced as a newly recommended treatment option [1] - Additionally, there are reports that the Centers for Medicare & Medicaid Services (CMS) in the U.S. has proposed a new RDN insurance coverage plan for patients with uncontrolled hypertension, which is currently in a 30-day public comment period, with a final decision expected by October 8, 2025 [1]

Core Viewpoint - The stock of Baixinan-B (02185) experienced significant volatility, with a peak increase of over 15% and a closing rise of more than 50% recently, indicating strong market interest and potential investor confidence in the company [1]. Group 1: Market Reaction - Baixinan-B's stock price rose by 11.4% to HKD 10.36, with a trading volume of HKD 42.644 million [1]. Group 2: Industry Developments - The American Heart Association (AHA) and the American College of Cardiology (ACC) released updated guidelines for the prevention, detection, assessment, and management of adult hypertension, marking significant revisions from the 2017 guidelines [1]. - The new guidelines include updates on the diagnosis, risk assessment, and treatment of hypertension, aiming to provide more precise clinical guidance to reduce cardiovascular disease (CVD) risk [1]. - Renal denervation (RDN) has been added as a recommended treatment option in the updated guidelines [1]. Group 3: Regulatory Changes - The Centers for Medicare & Medicaid Services (CMS) proposed a new RDN insurance coverage plan for patients with uncontrolled hypertension, which is currently in a 30-day public comment period [1]. - The final decision on the new RDN insurance proposal is expected to be announced by October 8, 2025, or earlier [1].

Core Viewpoint - The stock of Baixinan-B (02185) experienced significant volatility, with a rise of over 50% recently, driven by updates in hypertension management guidelines and potential insurance coverage for renal denervation (RDN) procedures [1]. Group 1: Stock Performance - Baixinan-B's stock rose over 15% at one point and closed up more than 50% yesterday, currently trading at 10.36 HKD with a trading volume of 42.644 million HKD [1]. Group 2: Industry Guidelines - The American Heart Association (AHA) and the American College of Cardiology (ACC) released updated guidelines for the prevention, detection, assessment, and management of adult hypertension, marking significant revisions from the 2017 guidelines [1]. - The new guidelines include updates on the diagnosis, risk assessment, and treatment of hypertension, aiming to provide more precise clinical guidance to reduce cardiovascular disease (CVD) risk [1]. Group 3: Insurance Coverage Proposal - The Centers for Medicare & Medicaid Services (CMS) proposed new insurance coverage for RDN, suggesting it be included for patients with uncontrolled hypertension [1]. - The proposal has entered a 30-day public comment period, with a final decision expected to be announced by October 8, 2025 [1].

Core Viewpoint - Baixinan-B (02185) experienced a significant increase of over 52% in stock price, reaching HKD 9.22 with a trading volume of HKD 98.296 million, following the announcement of its Iberis RDN system receiving a 5-year healthcare qualification in France [1] Group 1: Product Development and Market Expansion - The Iberis RDN system has been granted a 5-year healthcare qualification by French authorities, with the potential for renewal, enhancing the clinical application support system in Europe [1] - The company has also secured clinical application and guideline recommendations in Italy, Germany, and Spain [1] - In July, media reports indicated that the U.S. CMS proposed to include RDN in the healthcare coverage for patients with uncontrolled hypertension [1] Group 2: Clinical Success and Market Potential - In February, Baixinan's subsidiary, Shanghai Antong Medical, completed the first commercial procedure of the Iberis RDN system in Germany [1] - According to CITIC Securities, the RDN procedure shows significant and long-term effective blood pressure reduction, with a simple operation and low complication rates, indicating a broad long-term market potential [1] - The company's RDN products are advancing commercialization simultaneously in domestic and international markets, with a focus on the results of the first year of commercialization in 2025 [1]

Core Viewpoint - 百心安-B's stock surged over 52% following the announcement of its Iberis RDN system receiving a five-year healthcare qualification in France, indicating strong market potential and positive clinical developments [1] Company Developments - 百心安's Iberis RDN system has been granted a five-year healthcare qualification by French authorities, with the possibility of renewal, enhancing its clinical application support in Europe [1] - The company has also secured clinical application and guideline recommendations in Italy, Germany, and Spain [1] - In July, media reports indicated that the U.S. CMS proposed to include RDN in the healthcare coverage for patients with uncontrolled hypertension [1] Market Performance - As of the latest report, 百心安-B's stock price reached 9.22 HKD, with a trading volume of 98.2961 million HKD, reflecting strong investor interest [1] - 中信建投 highlighted the significant and long-term effectiveness of RDN in lowering blood pressure, along with its simple procedure and low complication rates, suggesting a broad long-term market potential [1] Commercialization Progress - 百心安's Iberis RDN system completed its first commercial procedure in Germany in February this year, marking a significant milestone in its commercialization efforts [1] - The company is advancing the commercialization of its RDN products both domestically and internationally, with a focus on the results of its first year of commercialization in 2025 [1]

Group 1 - The company, Baixinan-B (02185.HK), will hold a board meeting on August 26, 2025 [1] - The agenda includes reviewing and approving the interim results for the six months ending June 30, 2025, and discussing the proposal for an interim dividend, if any [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 Shanghai Bio-heart Biological Technology Co., Ltd. 上海百心安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 中 華 人 民 共 和 國 上 海，2025年8月14日 於 本 公 告 日 期，董 事 會 成 員 包 括 董 事 長 兼 執 行 董 事 汪 立 先 生；執 行 董 事 王 雲 磬 先 生 及 王 佩 麗 女 士；及 獨 立 非 執 行 董 事 陳 軼 青 先 生、魯 旭 波 先 生 及 蔣 一 斐 先 生。 （股 份 代 號：2185） 董事會會議召開日期 上 海 百 心 安 生 物 技 術 股 份 有 限 公 司（「本公司」）董 事 會（「董事會」）謹 此 宣 佈，本 公 司 將 於2025年8月26日（星 期 二）舉 ...

| 代码 | 简称 | 回购股数 | 回购金额（万 | 回购最高价 | 回购最低价 | 年内累计回购金额 | | --- | --- | --- | --- | --- | --- | --- | | | | （万股） | 港元） | （港元） | （港元） | （万港元） | | 00011 | 恒生银行 | 20.00 | 2289.15 | 115.100 | 113.200 | 11350.72 | | 02488 | 元征科技 | 35.10 | 425.10 | 12.260 | 12.000 | 4162.02 | | 08017 | 捷利交易 宝 | 40.00 | 55.89 | 1.400 | 1.380 | 3671.47 | | 01373 | 国际家居 零售 | 15.00 | 12.90 | 0.860 | 0.860 | 314.37 | | 02185 | 百心安-B | 51.99 | 0.00 | | | 0.00 | 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 （文章来源：证券时报网） 值得关注的是，百心安-B本次回购为年内首次进行回购。本次回购2289 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海百心安生物技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期： 2025年8月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02185 | 說明 | H股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 ...

第一章 總 則 章 程 2025年8月 – 1 – 上海百心安生物技術股份有限公司 上海百心安生物技術股份有限公司 章 程 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） 英 文 名 稱 為：Shanghai Bio-heart Biological Technology Co., Ltd. 第一條 上 海 百 心 安 生 物 技 術 股 份 有 限 公 司（以 下 簡 稱「公 司」）系 根 據《中 華 人 民 共 和 國 公 司 法》（以 下 簡 稱「《公 司 法》」）以 及 中 國 其 他 有 關 法 律、行 政 法 規 成 立 的 股 份 有 限 公 司。為 規 範 公 司 的 組 織 和 行 為，維 護 公 司、股 東 和 債 權 人 的 合 法 權 益，根 據《中 華 人 民 共 和 國 公 司 法》（以 下 簡 稱「《公 司 法》」）、《中 華 人 民 共 和 國 證 券 法》（以 下 簡 稱「《證 券 法》」）、《中 國 共 產 黨 黨 章》（以 下 簡 稱「黨 章」）、《香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則》（以 下 簡 稱「《上 ...